Office of Academic Resources
Chulalongkorn University
Chulalongkorn University

Home / Help

TitlePlatelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease [electronic resource] / edited by A. Michael Lincoff, Eric J. Topol
ImprintTotowa, NJ : Humana Press : Imprint: Humana Press, 1999
Connect tohttp://dx.doi.org/10.1007/978-1-59259-724-6
Descript XIV, 369 p. online resource

SUMMARY

In Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease, the major investigators working in this rapidly advancing field join together under the aegis of A. Michael Lincoff and Eric J. Topol to provide the first comprehensive overview of the preclinical and clinical development of the glycoprotein IIb/IIIa receptor antagonists. These acknowledged experts elucidate the theoretical basis for the inhibition of platelet aggregation in the treatment of coronary syndromes, present and synthesize evidence for the efficacy of glycoprotein IIb/IIIa blockade in inhibiting ischemic complications of both coronary intervention and acute coronary syndromes, and provide guidelines for the use of this novel class of agents in the clinical management of cardiovascular disease. They also compare the pharmacology and clinical efficacy of the currently available glycoprotein IIb/IIIa receptor inhibitors and speculate about further potential applications of these agents in the treatment of vascular disease. Written by the scientists and physicians who discovered and characterized this important new class of receptors, invented the first IIb/IIIa agents, and conducted the definitive clinical trials, Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease offers the most complete and authoritative review of these powerful new therapeutics available today


CONTENT

I Basic Principles -- 1 Thrombosis in Acute Coronary Syndromes and Coronary Interventions -- 2 Mechanisms of Platelet Adhesion -- 3 Glycoprotein IIb-IIIA in Platelet Aggregation and Acute Arterial Thrombosis -- 4 Glycoprotein IIb/IIIa Antagonists: Development of Abciximab and Pharmacology of Select Agents -- II Glycoprotein IIB/IIIA Blockade During Coronary Intervention -- 5 Abciximab in Coronary Interventionโ{128}{148}The EPIC, EPILOG, EPISTENT Trials -- 6 Eptifibatide in Coronary Interventionโ{128}{148}The IMPACT Trials -- 7 Tirofiban in Coronary Interventionโ{128}{148}The RESTORE Trial -- 8 The Use of Abciximab in Therapy Resistant Unstable Angina: Clinical and Angiographic Results of the CAPTURE Pilot and the CAPTURE Study -- 9 Overview of the Glycoprotein IIb/IIIa Inhibitor Interventional Trials -- III Glycoprotein IIb/IIIa Blockade for Ischemic Syndromes -- 10 Unstable Angina: PURSUIT, PARAGON, PRISM, and PRISM PLUS -- 11 The Use of Glycoprotein IIb/IIIa Inhibition in Acute Myocardial Infarction -- IV Practical Issues and Future Applications -- 12 Economics of Glycoprotein IIb/IIIa Inhibition -- 13 Monitoring Platelet Aggregation -- 14 Oral Platelet Glycoprotein IIb/IIIa Blockade -- 15 Cerebrovascular Aspects of Glycoprotein IIb/IIIa Inhibitors -- 16 The Future of Glycoprotein IIb/IIIa Inhibitors


Medicine Cardiology Medicine & Public Health Cardiology



Location



Office of Academic Resources, Chulalongkorn University, Phayathai Rd. Pathumwan Bangkok 10330 Thailand

Contact Us

Tel. 0-2218-2929,
0-2218-2927 (Library Service)
0-2218-2903 (Administrative Division)
Fax. 0-2215-3617, 0-2218-2907

Social Network

  line

facebook   instragram